Publication | Closed Access

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

Metastatic Breast CancerBreast OncologyMedicinePharmacologyGynecologyBreast CancerPharmacotherapyMenopauseMature ResultsOncologyExemestane Versus TamoxifenEndocrine-related CancerMenopause Hormone Therapy